Does Xgeva Cause Jaw Necrosis?
Yes, Xgeva (denosumab) causes osteonecrosis of the jaw (ONJ), also called medication-related osteonecrosis of the jaw (MRONJ), in some patients. This rare but serious side effect involves exposed jawbone that fails to heal for over eight weeks, often after dental procedures. Clinical trials showed ONJ in 1.8-2.2% of Xgeva users versus 0.7% on placebo, with higher rates (up to 4.9%) in long-term use for bone metastases.[1][2]
How Common Is Jaw Necrosis with Xgeva?
Incidence varies by patient group:
- Cancer patients with bone metastases: 1-2% in first year, rising to 7% after four years.
- Osteoporosis patients: Lower, around 0.04-0.1% per year.
Risk increases with duration (over two years), oral surgery, poor dental hygiene, smoking, or diabetes. Post-marketing reports confirm hundreds of cases.[1][3]
Why Does Xgeva Cause Jaw Necrosis?
Xgeva blocks RANKL, a protein needed for osteoclasts that remodel bone. Jaws remodel rapidly due to chewing and teeth, so suppression starves bone cells, impairing repair after injury like tooth extraction. Unlike bisphosphonates (e.g., Zometa), Xgeva clears faster from blood but lingers in bone.[2][4]
How Does Xgeva Compare to Other Bone Drugs for Jaw Risk?
| Drug | Class | ONJ Risk (Cancer Patients) | Notes |
|------|-------|----------------------------|-------|
| Xgeva (denosumab) | RANKL inhibitor | 1-7% (dose/duration-dependent) | Reversible upon stopping; lower tooth extraction risk vs. Zometa. |
| Zometa (zoledronic acid) | IV bisphosphonate | 1-10% | Stays in bone longer; higher cumulative risk. |
| Prolia (denosumab, lower dose) | Same as Xgeva | 0.01-0.1% | Used for osteoporosis; similar mechanism. |
| Oral bisphosphonates (e.g., Fosamax) | Oral bisphosphonates | <0.1% | Much lower due to poor jaw uptake. |
Xgeva has comparable or slightly lower ONJ risk than IV bisphosphonates in head-to-head trials.[1][5]
What Do Patients Experience with Jaw Necrosis?
Symptoms include jaw pain, swelling, loose teeth, exposed bone, or infection. Cases can require surgery, antibiotics, or hyperbaric oxygen; some heal after stopping Xgeva, but 20-30% persist. Patient forums report cases after routine dentistry, with delays in diagnosis.[3][6]
How to Prevent Jaw Necrosis on Xgeva?
- Complete dental checkup before starting.
- Avoid invasive dental work during first months; use preventive care.
- Maintain oral hygiene; quit smoking.
- FDA recommends risk assessment; some guidelines suggest drug holidays before extractions.[1][2]
Regulatory Warnings and Studies
Xgeva's label carries a black box warning for ONJ since 2010 approval. Large trials (e.g., 5,786-patient cancer study) and registries track rates. No full cure exists, but early intervention helps.[1][7]
Sources:
[1] Xgeva Prescribing Information, FDA: https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/125320s205lbl.pdf
[2] ASCO Guidelines on Bone-Modifying Agents: https://ascopubs.org/doi/full/10.1200/JCO.20.01788
[3] AAOMS Position Paper on MRONJ: https://aaoms.org/wp-content/uploads/2024/01/mronj-position-paper.pdf
[4] NEJM Trial (Denosumab vs. Zoledronic Acid): https://www.nejm.org/doi/full/10.1056/NEJMoa0910630
[5] Lancet Oncology Review: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30242-6/fulltext
[6] DrugPatentWatch.com (Xgeva Safety Data): https://www.drugpatentwatch.com/p/tradename/XGEVA
[7] EMA Xgeva Summary: https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-informationen.pdf